Ulcerative Colitis Pipeline and Clinical Trials Assessment, 2024 Updates: FDA Approvals, Therapies and Key Companies involved by DelveInsight | NuBiyota, Adiso Therapeutics, Landos Biopharma, Prometheus Biosciences, OSE Immunotherapeutics, AstraZeneca, Mo

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Ulcerative Colitis pipeline constitutes 110+ key companies continuously working towards developing 110f+ Ulcerative Colitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Ulcerative Colitis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ulcerative Colitis Market.

The Ulcerative Colitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Ulcerative Colitis Pipeline Report: https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Ulcerative Colitis treatment therapies with a considerable amount of success over the years.
• Ulcerative Colitis companies working in the treatment market are NuBiyota, Adiso Therapeutics, Landos Biopharma, Prometheus Biosciences, OSE Immunotherapeutics, AstraZeneca, Morphic Therapeutic, AbbVie, InDex Pharmaceuticals, Pfizer, Palatin Technologies, Inc, Eli Lilly and Company, Janssen Research & Development, LLC, Amgen, Landos Biopharma Inc., Mesoblast, Inc., Bristol-Myers Squibb, Abivax S.A., Oppilan Pharma Ltd, EA Pharma Co., Ltd., Prometheus Biosciences, Inc., Sanofi, Galapagos NV, Celgene, and others, are developing therapies for the Ulcerative Colitis treatment
• Emerging Ulcerative Colitis therapies in the different phases of clinical trials are- MET-2, BT051, NX-13, PRA023, OSE-127, Brazikumab, MORF-057, Risankizumab, Cobitolimod, Etrasimod, PL8177, Mirikizumab, Guselkumab, Efavaleukin alfa, NX-13, Remestemcel-L, Ozanimod, ABX464, VTX002, AJM300, PRA023 IV, SAR443122, GLPG3970, Ozanimod, and others are expected to have a significant impact on the Ulcerative Colitis market in the coming years.
• In December 2023, Insilico Medicine, headquartered in Hong Kong, has initiated a Phase I clinical trial for its AI-discovered drug ISM5411. The trial (NCT06012578) will focus on assessing the drug's safety, tolerability, pharmacokinetics, and food effects in healthy volunteers. It aims to enroll approximately 76 healthy volunteers across Australia, with anticipated results expected by the conclusion of 2024. Insilico has completed dosing in two single ascending dose (SAD) groups as well as a 200mg dose group. The company's plans entail including seven SAD groups and three groups for multiple ascending doses (MAD) in the Phase I trial.
• In July 2023, the Phase 3 Step-Up HS study, which is evaluating upadacitinib (RINVOQ®) in adults and children with moderate to severe hidradenitis suppurativa (HS) who have failed anti-tumor necrosis factor (TNF) therapy and/or one approved non-anti-TNF inhibitor therapy, has dosed its first patient, according to AbbVie (NYSE: ABBV).
• In June 2023, The novel medication mirikizumab, which Amsterdam UMC and collaborators from around the world are researching, is successful in treating ulcerative colitis. The clinical experiment showed that in some groups, the rates of remission doubled, reaching up to 50%
• In June 2023, The first patients in a Phase I clinical study of MAP 315, a live biotherapeutic product being developed for the treatment of ulcerative colitis (UC), were dosed by Microba Life Sciences

Ulcerative Colitis Overview
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) characterized by inflammation and ulcers in the lining of the colon and rectm. It is believed to be caused by an abnormal immune response in which the body's immune system mistakenly attacks healthy tissues in the gastrointestinal tract.

Get a Free Sample PDF Report to know more about Ulcerative Colitis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/ulcerative-colitis-uc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Ulcerative Colitis Drugs Under Different Phases of Clinical Development Include:
• PRA023: Prometheus Biosciences
• OSE-127: OSE Immunotherapeutics
• Brazikumab: AstraZeneca
• MORF-057: Morphic Therapeutic
• Risankizumab: AbbVie
• Cobitolimod: InDex Pharmaceuticals
• Etrasimod: Pfizer
• PL8177: Palatin Technologies, Inc
• Mirikizumab: Eli Lilly and Company
• Guselkumab: Janssen Research & Development, LLC
• Efavaleukin alfa: Amgen
• NX-13: Landos Biopharma Inc.
• Remestemcel-L: Mesoblast, Inc.
• Ozanimod: Bristol-Myers Squibb
• ABX464: Abivax S.A.
• VTX002: Oppilan Pharma Ltd
• AJM300: EA Pharma Co., Ltd.
• PRA023 IV: Prometheus Biosciences, Inc.
• SAR443122: Sanofi
• GLPG3970: Galapagos NV
• Ozanimod: Celgene

Ulcerative Colitis Route of Administration
Ulcerative Colitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Ulcerative Colitis Molecule Type
Ulcerative Colitis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Ulcerative Colitis Pipeline Therapeutics Assessment
• Ulcerative Colitis Assessment by Product Type
• Ulcerative Colitis By Stage and Product Type
• Ulcerative Colitis Assessment by Route of Administration
• Ulcerative Colitis By Stage and Route of Administration
• Ulcerative Colitis Assessment by Molecule Type
• Ulcerative Colitis by Stage and Molecule Type

DelveInsight's Ulcerative Colitis Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Ulcerative Colitis product details are provided in the report. Download the Ulcerative Colitis pipeline report to learn more about the emerging Ulcerative Colitis therapies at:
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Ulcerative Colitis Therapeutics Market include:
Key companies developing therapies for Ulcerative Colitis are - Merck & Co., Inc.,, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Eli Lilly and Company, AbbVie Inc. (Allergan, Inc.), Bausch Health Companies Inc., Johnson and Johnson, Novartis AG, Bristol Myers Squibb, Mitsubishi Tanabe Pharma Corporation, Sun Pharmaceutical Industries Ltd., and others.

Ulcerative Colitis Pipeline Analysis:
The Ulcerative Colitis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Ulcerative Colitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ulcerative Colitis Treatment.
• Ulcerative Colitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Ulcerative Colitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ulcerative Colitis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Ulcerative Colitis drugs and therapies-
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Ulcerative Colitis Pipeline Market Drivers
• Increasing awareness and R&D investment, emergence of large number of novel pipeline molecules with great market potential are some of the important factors that are fueling the Ulcerative Colitis Market.

Ulcerative Colitis Pipeline Market Barriers
• However, side effects associated with the treatment, high cost treatment and other factors are creating obstacles in the Ulcerative Colitis Market growth.

Scope of Ulcerative Colitis Pipeline Drug Insight
• Coverage: Global
• Key Ulcerative Colitis Companies: NuBiyota, Adiso Therapeutics, Landos Biopharma, Prometheus Biosciences, OSE Immunotherapeutics, AstraZeneca, Morphic Therapeutic, AbbVie, InDex Pharmaceuticals, Pfizer, Palatin Technologies, Inc, Eli Lilly and Company, Janssen Research & Development, LLC, Amgen, Landos Biopharma Inc., Mesoblast, Inc., Bristol-Myers Squibb, Abivax S.A., Oppilan Pharma Ltd, EA Pharma Co., Ltd., Prometheus Biosciences, Inc., Sanofi, Galapagos NV, Celgene, and others
• Key Ulcerative Colitis Therapies: MET-2, BT051, NX-13, PRA023, OSE-127, Brazikumab, MORF-057, Risankizumab, Cobitolimod, Etrasimod, PL8177, Mirikizumab, Guselkumab, Efavaleukin alfa, NX-13, Remestemcel-L, Ozanimod, ABX464, VTX002, AJM300, PRA023 IV, SAR443122, GLPG3970, Ozanimod, and others
• Ulcerative Colitis Therapeutic Assessment: Ulcerative Colitis current marketed and Ulcerative Colitis emerging therapies
• Ulcerative Colitis Market Dynamics: Ulcerative Colitis market drivers and Ulcerative Colitis market barriers

Request for Sample PDF Report for Ulcerative Colitis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Ulcerative Colitis Report Introduction
2. Ulcerative Colitis Executive Summary
3. Ulcerative Colitis Overview
4. Ulcerative Colitis- Analytical Perspective In-depth Commercial Assessment
5. Ulcerative Colitis Pipeline Therapeutics
6. Ulcerative Colitis Late Stage Products (Phase II/III)
7. Ulcerative Colitis Mid Stage Products (Phase II)
8. Ulcerative Colitis Early Stage Products (Phase I)
9. Ulcerative Colitis Preclinical Stage Products
10. Ulcerative Colitis Therapeutics Assessment
11. Ulcerative Colitis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Ulcerative Colitis Key Companies
14. Ulcerative Colitis Key Products
15. Ulcerative Colitis Unmet Needs
16 . Ulcerative Colitis Market Drivers and Barriers
17. Ulcerative Colitis Future Perspectives and Conclusion
18. Ulcerative Colitis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Ulcerative Colitis Market https://www.delveinsight.com/report-store/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Ulcerative Colitis-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Ulcerative Colitis Epidemiology https://www.delveinsight.com/report-store/ulcerative-colitis-uc-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Ulcerative Colitis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2030' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Iga Nephropathy Market
https://www.delveinsight.com/report-store/iga-nephropathy-market
DelveInsight's "IgA Nephropathy Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of the IgA Nephropathy, historical and forecasted epidemiology as well as the IgA Nephropathy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China.

Vutrisiran Market
https://www.delveinsight.com/report-store/vutrisiran-market
DelveInsight's "Vutrisiran Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Vutrisiran, historical and forecasted epidemiology as well as the Vutrisiran market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Gastroesophageal Reflux Disease Market
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market
DelveInsight's "Gastroesophageal Reflux Disease (GERD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Gastroesophageal Reflux Disease (GERD), historical and forecasted epidemiology as well as the Gastroesophageal Reflux Disease (GERD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.